In contrast to previous study findings, inhaled corticosteroids do not appear to increase risk for pneumonia in patients with COPD with moderate airflow limitation.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
Strictly following empirical antimicrobial treatment guidelines in patients with hospital-acquired or ventilator-associated pneumonia may result in overtreatment with antibiotics.
Study results indicate that delafloxacin has potent in-vitro activity against most common pathogens seen in community-acquired pneumonia.
After 6 months of use, over half of patients who used the Remedē System experienced a 50% or greater reduction in the apnea-hypopnea index.
Survival rates do not improve with nitric oxide in premature infants without bronchopulmonary dysplasia.
Combination antibiotic therapy with a macrolide improves hospital length of stay in patients with severe community-acquired pneumonia.
Palliative care access may be limited for patients with cystic fibrosis.
Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.
Compared with fine particle inhaled corticosteroids, extrafine particle inhaled corticosteroids helped patients achieve asthma control.
Montelukast is associated with depression, aggression, and nightmares in children.
Patients with clinical markers of greater asthma severity may experience a more significant reduction of exacerbations when treated with omalizumab.
Low education and low income are linked to lower uptakes of PCV13 in minorities 65 years and older.
Investigators found that macrolides correlated with lower odds of treatment failure in patients younger than 5 with CAP.
Using serum procalcitonin levels to diagnose and manage bacterial pneumonia decreases length of hospital stay.
Overall and progression-free survival were improved with greater depth of response to therapy in non-small cell lung cancer.
Long-acting muscarinic antagonists plus long-acting beta-agonists for COPD is associated with fewer exacerbations compared with long-acting beta-agonists plus inhaled corticosteroids.
Patients with COPD who have elevated blood eosinophilic levels may benefit from treatment with mepolizumab.
Patients with severe obstructive sleep apnea who use continuous positive airway pressure therapy may experience a decrease in carotid intima-media thickness.
Patients with metastatic lung cancer who receive both both immune checkpoint inhibitors and thoracic radiotherapy.do not have a greater risk for immune-related adverse events.
Children who discontinue inhaled corticosteroids for well-controlled asthma may experience worsening symptoms.
Adjuvant adoptive cellular immunotherapy plus chemotherapy improved survival in patients with resected non-small cell lung caner.
Thoroughness of nodal examination determines prognostic value of non-small cell lung cancer staging.
Higher doses of chemoradiation in stage 3 non-small cell lung cancer did not improve overall survival rates.
Fluticasone furoate plus vilanterol therapy offers long-term asthma control without serious adverse events.
Early initiation of folic acid or prenatal vitamin supplementation may protect the offspring of mothers who have a history of atopy from adverse childhood respiratory outcomes.
A low tidal volume ventilation strategy in patients with acute respiratory distress syndrome demonstrated a trend toward improved mortality.
Forced expiratory volume in 1 second and length of hospital stay were assess to determine the benefit of endobronchial valve placement vs standard of care in emphysema.
The prevalence of smoking is higher in people who have experienced myocardial infarction.
Identifying gender-based differences in asthma follow-ups is crucial to understanding sex-based differences in health behaviors.
In patients with mild or moderate chronic obstructive pulmonary disease, tiotropium improved the decline in FEV1, as well as quality of life.
Diet and exercise appeared to improve asthma symptom control, overall fitness, and quality of life.
Researchers examined the efficacy of tezepelumab, a human monoclonal antibody, in treating moderate to severe asthma with non-eosinophilic inflammation.
There may be a decreased rate of lung cancer for patients who receive anti-inflammatory therapy with canakinumab.
Patients with COPD and comorbid cardiovascular disease may benefit from statin treatment depending on their C - reactive protein levels.
Bevacizumab-awwb was approved based on pharmacokinetic and pharmacodynaic profiles and immunogenicity, safety, and efficacy data.
Pediatric patients with asthma are at the highest risk for adverse drug events, particularly with inhaled corticosteroids.
Two phase 3 clinical trials examined mepolizumab 100 or 300 mg vs placebo to treat moderate-to-severe COPD exacerbations.
Participants received web-based OSA education, CPAP telemonitoring with automated feedback, both, or usual care.
Oral corticosteroids did not reduce symptom severity or duration in patients with lower respiratory tract infections without asthma.
Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.
Canakinumab vs placebo showed promising results in preventing recurrent cardiovascular events and incidences of lung cancer.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
Asking patients to stop smoking before undergoing cosmetic surgery can promote long-term smoking cessation with 40.5% of participants in a recent study no longer smoking on a daily basis.
People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.
Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.
The correlation between patient race and ethnicity and administration of antibiotic treatment for viral acute respiratory tract infections was examined.
Adults with asthma benefit from tailoring interventions based on sputum eosinophils vs clinical symptoms.
Researchers analyzed over 2.1 million patient-years' worth of data to determine the impact of short-acting beta agonist use in asthma.
Participants received 70 mg of tezepelumab every 4 weeks throughout the study.
A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.
FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.
Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.
Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.
The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.
Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.
The pathogeneses of steroid insensitivity in severe, steroid-resistant asthma may unlock new potential treatments.
Fluticasone furoate and vilanterol combination therapy reduced both daytime and nighttime symptoms in patients with persistent uncontrolled asthma.
Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.
Only 22.7% of smokers with coronary heart disease received some kind of smoking cessation pharmacotherapy during their hospitalization.
Study results showed the benefit of single-inhaler triple therapy vs ICS/LABA therapy in COPD.
Researchers found a weak negative association between PCT testing rate and risk-adjusted antibiotic initiation rate.
Patients who underwent alternative therapies were more likely to die vs those who underwent usual care.
Patients had similar outcomes with standardized treatment for community-acquired pneumococcal pneumonia regardless of HIV status.
Inhaled corticosteroids for COPD does not increase the risk for fractures when used for short-term periods.
Data from the 2015-2016 season shows that the live attenuated influenza vaccine was ineffective among children ages 2-17.
Timely selection and early intervention, attention to comfort, and frequent checks improved outcomes in patients with chronic obstructive pulmonary disease who were treated with noninvasive ventilation.
Chronic obstructive pulmonary disease may be misdiagnosed in patients as a result of errors related to spirometry tests, errors made in primary care, and differential diagnoses, among others.
A case report describes a woman who presented to the emergency room 12 hours after choking while taking her iron supplement which caused severe cough and wheezing.
Patients with hereditary angioedema treated with icatibant had similar outcomes regardless of whether they were on long-term prophylaxis.
A systematic review examined the safety and cost-effectiveness of allergen immunotherapy for allergic rhinitis, allergic asthma, food allergy, and venom allergy.
Incidence of delirium and coma were not prevented with early initiation of simvastatin in patients on mechanical ventilation.
A single-center study found that omalizumab led to reductions in allergic response much earlier than previously demonstrated.
ASCO has released updated guidelines to help physicians manage nausea and vomiting caused by antineoplastic agents in cancer patients.
Vaccinations include Fluad, Flucelvax Quadrivalent, Afluria Quadrivalent, and Fluvirin,
While counseling is common, few patients are actually prescribed a smoking cessation medication.
Researchers sought to analyze previous data in a real-world context.
Nasal hyperreactivity was predictive of treatment success.
In children with allergic asthma and rhinitis, sublingual immunotherapy (SLIT) was shown to not only improve patient-reported symptoms, but also airway inflammation and pulmonary function.
Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.
The oral antifungal is a promising, highly potent, highly selective drug with broad-spectrum antifungal activity.
Researchers examined structural social support indicators, including living status, having a partner, number of close friends and relatives, and the presence of a family caregiver.
When general practitioners refer patients to asthma diagnostic consultation services asthma diagnosis improved.
Researchers considered the response rate "encouraging" and comparable to cisplatin-based neoadjuvant therapy outcomes.
Hyperbaric oxygen therapy use is increasingly used among elderly patients and patients with diabetes, despite ADA concerns.
Cardio- and cerebrovascular events were more common in patients being treated with combination long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) therapies vs LABA/inhaled corticosteroids.
The first study of antibiotic use in outpatients with COPD exacerbations found that doxycycline plus prednisone did not prolong the time between exacerbations.
The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.
Mechanical ventilation does not improve outcomes in IPF patients, lengthens hospital stays, and increases costs.
The first study to examine patient positioning during intubation outside of the operating room yields surprising results.
Azithromycin reduced exacerbations and improved quality of life in adults with asthma in a randomized double-blind placebo-controlled trial.
Does Maintenance Pembrolizumab Improve Progression-Free, Overall Survival in Small-cell Lung Cancer?
Pembrolizumab may improve survival among patients with ES-SCLC
Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.
Results showed that proton-beam therapy in small-cell lung cancer can be safe in combined modality therapy.
Findings in patients with previously untreated disease with PD-L1 expression level of 5%.
Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.
Watching a tape of themselves struggling to sleep increases CPAP adherence in patients with OSA.
Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.
Treatment with CPAP doesn't doesn't reduce risk of cardiovascular related outcomes.
Azithromycin therapy is more effective at preventing COPD exacerbations among patients with Helicobacter pylori infection than among those who are H pylori seronegative.